<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Familial Mediterranean Fever - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Familial Mediterranean Fever</span>
        </nav>

        <header class="page-header">
            <h1>Familial Mediterranean Fever</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0018088" target="_blank">
                        MONDO:0018088
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoinflammatory Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inherited Disorder</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
        </div>

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Type 1</div>
                
                <div class="item-desc">Classic form presenting with recurrent episodes of fever and serositis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25649364" target="_blank">PMID:25649364</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean Fever is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis."</div>
                
                
                <div class="evidence-explanation">Although the literature describes Familial Mediterranean Fever having episodic fever and serositis, it does not define subtypes or a &#39;Type 1&#39; specifically.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23823268" target="_blank">PMID:23823268</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Periodic fevers are acquired or inherited disorders of innate immunity, which were first described in the 1940s. ... This clinical review focuses on a sample of autoinflammatory disorders including familial Mediterranean fever..."</div>
                
                
                <div class="evidence-explanation">There is a general discussion of Familial Mediterranean Fever but no mention of subtypes or a classification system involving the term &#39;Type 1&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36889987" target="_blank">PMID:36889987</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"MEFV gene mutation spectrum in patients with familial mediterranean fever."</div>
                
                
                <div class="evidence-explanation">This study discusses the gene mutations associated with FMF but does not describe subtypes of the disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Type 2</div>
                
                <div class="item-desc">A variant characterized by continuous subclinical inflammation, leading to amyloidosis without overt episodes.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21358337" target="_blank">PMID:21358337</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual."</div>
                
                
                <div class="evidence-explanation">The literature directly states that FMF type 2 is characterized by amyloidosis without prior overt inflammatory episodes, aligning with the given statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11053071" target="_blank">PMID:11053071</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Phenotype II in familial Mediterranean fever (FMF) is the onset of amyloidosis before the onset of FMF with its typical attacks, or as an isolated finding in a member of an FMF family."</div>
                
                
                <div class="evidence-explanation">While this states Type 2 can involve amyloidosis without typical attacks, it does not directly mention continuous subclinical inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36161616" target="_blank">PMID:36161616</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis."</div>
                
                
                <div class="evidence-explanation">Reference to subclinical inflammation in amyloidosis supports part of the statement, but does not specifically mention Type 2 FMF.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">MEFV Gene Mutation</div>
                
                <div class="item-desc">Mutations in the MEFV gene lead to dysfunctional pyrin, causing excessive inflammation.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28154935" target="_blank">PMID:28154935</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean fever (FMF) is caused by mutations within the Mediterranean fever (MEFV) gene. These gain of function mutations lead to an increased activation of the inflammasome pyrin with a subsequent disproportional proinflammatory reaction."</div>
                
                
                <div class="evidence-explanation">Mutations in the MEFV gene result in increased activation of pyrin, causing excessive inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25307949" target="_blank">PMID:25307949</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in the MEFV gene are associated with the human autoinflammatory disease familial Mediterranean fever (FMF). Pyrin can interact with the inflammasome adaptor ASC and induce inflammatory caspase-1 activation in monocytic cells."</div>
                
                
                <div class="evidence-explanation">This article discusses the role of pyrin in inducing inflammatory responses, supporting the effect of MEFV gene mutations in causing excessive inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36889987" target="_blank">PMID:36889987</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"MEFV gene mutation spectrum in patients with familial mediterranean fever"</div>
                
                
                <div class="evidence-explanation">The mutation spectrum in the MEFV gene is related to the pathogenesis involving pyrin and inflammation, supporting the given statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autoinflammatory Pathway Activation</div>
                
                <div class="item-desc">Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16344627" target="_blank">PMID:16344627</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The spectrum of reported genetic mutations and susceptible ethnicities for the hereditary periodic fever subset of the autoinflammatory diseases has continued to expand. At the same time, the pathogeneses of many of these diseases are now understood to involve different aspects of a common..."</div>
                
                
                <div class="evidence-explanation">This reference supports the involvement of IL-1 and inflammatory pathways in autoinflammatory diseases, including Familial Mediterranean Fever (FMF).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29148036" target="_blank">PMID:29148036</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pyrin, encoded by the MEFV gene, is an intracellular pattern recognition receptor that assembles inflammasome complexes in response to pathogen infections. Mutations in the MEFV gene have been linked to autoinflammatory diseases such as familial Mediterranean fever (FMF) or pyrin-associated..."</div>
                
                
                <div class="evidence-explanation">This reference describes the role of pyrin in inflammasome activation and its link to FMF, supporting the statement about dysregulated inflammatory responses and recurrent inflammatory episodes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33026080" target="_blank">PMID:33026080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"FMF is an autoinflammatory disease characterized by recurrent attacks and increased IL-1 synthesis owing to activation of the pyrin inflammasome"</div>
                
                
                <div class="evidence-explanation">This reference directly mentions recurrent attacks and increased IL-1 synthesis due to pyrin inflammasome activation, supporting the mechanisms described in the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Recurrent Fever
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001954" target="_blank">
                            HP:0001954
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21358337" target="_blank">PMID:21358337</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean fever type 1 is characterized by recurrent short episodes of inflammation and serositis, including fever, peritonitis, synovitis, pleuritis, and, rarely, pericarditis."</div>
                
                
                <div class="evidence-explanation">The literature supports that recurrent fever is a common feature of Familial Mediterranean Fever type 1, but it does not fully support that FMF should be categorized solely under systemic phenotypes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25832989" target="_blank">PMID:25832989</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean fever...presents with recurrent and self-limited inflammatory attacks of fever and polyserositis along with high acute-phase reactants."</div>
                
                
                <div class="evidence-explanation">The literature supports that recurrent fever is a common diagnostic feature of FMF and systemically involves fever and inflammation, but it does not confirm all specified aspects of the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36688581" target="_blank">PMID:36688581</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Higher Pras scores, earlier age of symptoms and diagnosis, more frequent arthritis and erysipelas-like erythema, and higher colchicine dose are closely associated with M694V homozygous familial Mediterranean fever patients. These patients also have mostly moderate and severe disease severity."</div>
                
                
                <div class="evidence-explanation">It supports the systemic nature and severity aspects but does not fully align with the complete statement&#39;s focus.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Arthritis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001369" target="_blank">
                            HP:0001369
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Transient, affecting large joints</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11411958" target="_blank">PMID:11411958</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The arthritis was transient, monoarticular, nonerosive, and nondeforming in the majority of cases. Four patients (5.4%) had chronic arthritis, with one requiring total hip replacement. As in previous reports on arthritis of FMF, the majority of FMF patients studied in Lebanon had a transient..."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that arthritis is a common phenotype in FMF, is transient, and affects large joints.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33124556" target="_blank">PMID:33124556</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"More patients had arthritis in the ELE group than in the other group (p=0.011). Arthritis occurred in the ankle (77.4%), knee (19.3%) and hip (3.2%) joints."</div>
                
                
                <div class="evidence-explanation">This reference confirms the presence of arthritis in FMF patients, especially in large joints, supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Peritonitis
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002586" target="_blank">
                            HP:0002586
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Recurrent abdominal pain due to inflammation of the peritoneum</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36082189" target="_blank">PMID:36082189</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"FMF is characterised by dysregulation of the inflammatory process in the body, presenting as recurrent episodes of serositis. Patients with FMF commonly present with episodes of fever, peritonitis, synovitis, pleuritis, arthritis, and occasionally pericarditis."</div>
                
                
                <div class="evidence-explanation">This reference supports that peritonitis, which involves abdominal pain due to inflammation of the peritoneum, is a phenotype of FMF. However, it does not explicitly indicate a high frequency of gastrointestinal phenotypes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37723615" target="_blank">PMID:37723615</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean fever (FMF) is the most prevalent hereditary autoinflammatory disease among children. Abdominal pain and various gastrointestinal system (GIS) manifestations may arise directly from FMF or concomitantly with FMF."</div>
                
                
                <div class="evidence-explanation">This reference supports that gastrointestinal manifestations, including abdominal pain, are phenotypes of FMF. However, it does not specify the high frequency of peritonitis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/9562837" target="_blank">PMID:9562837</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"When a patient complains of episodic fever accompanied by unexplained arthritis, peritonitis, pleurisy, or skin rash, this disorder should be considered."</div>
                
                
                <div class="evidence-explanation">This reference supports that peritonitis is a common phenotype of FMF, aligning well with the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Pleuritis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Thoracic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002102" target="_blank">
                            HP:0002102
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Recurrent chest pain due to inflammation of the pleura</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38204312" target="_blank">PMID:38204312</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common signs and symptoms are fever, abdominal pain, chest pain, and arthritis."</div>
                
                
                <div class="evidence-explanation">The study highlights chest pain as a frequent symptom in FMF patients, indicating pleuritis as a common phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12092043" target="_blank">PMID:12092043</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lung involvement in FMF is limited mainly to transient pleuritis during acute attacks."</div>
                
                
                <div class="evidence-explanation">The study specifies that pleuritis, which is inflammation of the pleura, is a frequent thoracic phenotype in FMF.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36385047" target="_blank">PMID:36385047</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pericarditis, pleurisy and the response to colchicine indicated FMF."</div>
                
                
                <div class="evidence-explanation">This study identifies pleurisy, another term for pleuritis, as a characteristic symptom in FMF patients, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Amyloidosis
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Renal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0011034" target="_blank">
                            HP:0011034
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Can lead to kidney failure if untreated</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12832747" target="_blank">PMID:12832747</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Amyloidosis, causing renal failure, is one of the most severe complications of the disease."</div>
                
                
                <div class="evidence-explanation">The literature confirms that amyloidosis can lead to kidney failure in patients with Familial Mediterranean Fever (FMF), supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23548761" target="_blank">PMID:23548761</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Familial Mediterranean Fever and tuberculosis were the most frequent causes of amyloidosis."</div>
                
                
                <div class="evidence-explanation">The statement is supported as FMF is listed as one of the frequent causes of renal amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21360109" target="_blank">PMID:21360109</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most frequent cause [of renal amyloidosis in children] is now autoinflammatory diseases. Among this group of diseases, the most frequent one throughout the world is familial Mediterranean fever (FMF)."</div>
                
                
                <div class="evidence-explanation">This confirms that FMF is a frequent cause of renal amyloidosis, thereby supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Erysipelas-Like Erythema
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Integumentary</span>
                    
                    
                </div>
                
                <div class="item-desc">Recurrent erythematous skin lesions, usually on the lower legs</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21352275" target="_blank">PMID:21352275</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Erysipelas-like erythema with familial Mediterranean fever."</div>
                
                
                <div class="evidence-explanation">The title itself indicates a connection between erysipelas-like erythema and familial Mediterranean fever.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33124556" target="_blank">PMID:33124556</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Erysipelas-like erythema (ELE) is a well-known pathognomonic skin lesion associated with familial Mediterranean fever (FMF)."</div>
                
                
                <div class="evidence-explanation">The study describes ELE as a significant feature of FMF, supporting the statement that it is an occasional manifestation in the integumentary system.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Myalgia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003326" target="_blank">
                            HP:0003326
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Muscle pain, often in the legs, associated with fever episodes</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37309906" target="_blank">PMID:37309906</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recurrent fever, serositis, and arthritis are common findings of the disease. In addition, musculoskeletal complaints such as exertional leg pain can be overlooked, although they are common and affect patients&#39; quality of life."</div>
                
                
                <div class="evidence-explanation">The literature mentions musculoskeletal complaints, including exertional leg pain, as common in FMF, supporting the statement that myalgia is an occasional symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32895731" target="_blank">PMID:32895731</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Protracted febrile myalgia syndrome (PFMS) is one of the rare conditions characterized by long standing severe myalgia and fever in familial Mediterranean fever (FMF) patients."</div>
                
                
                <div class="evidence-explanation">This reference specifically mentions severe myalgia as a symptom in FMF patients, which supports the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Colchicine
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19797919" target="_blank">PMID:19797919</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The study demonstrated that colchicine treatment is effective in preventing amyloidosis among Armenian patients with FMF and that earlier initiation and continuous therapy at an adequate dose of 1.2-1.8 mg/day may be associated with a decreased amyloidosis risk among Armenian patients with FMF."</div>
                
                
                <div class="evidence-explanation">The study directly supports the statement that colchicine is a first-line treatment for preventing amyloidosis, a common complication of FMF.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25649364" target="_blank">PMID:25649364</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The only agent that decreases the development of amyloidosis and the frequency and severity of the episodes is colchicine, which has been used for about 40 years."</div>
                
                
                <div class="evidence-explanation">This reference clearly supports the claim that colchicine reduces the frequency of attacks and prevents amyloidosis, affirming its role as a first-line treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25791871" target="_blank">PMID:25791871</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Early studies reported colchicine as a potential drug for preventing attacks of familial Mediterranean fever."</div>
                
                
                <div class="evidence-explanation">This indicates that colchicine is considered effective for preventing FMF attacks, supporting its position as a first-line treatment.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Anti-IL-1 Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28362189" target="_blank">PMID:28362189</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life."</div>
                
                
                <div class="evidence-explanation">The reference supports the use of anti-IL-1 therapy for treating colchicine-resistant FMF cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30338514" target="_blank">PMID:30338514</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"For those people who are colchicine-resistant or intolerant, drugs such as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and interferon-alpha might be beneficial."</div>
                
                
                <div class="evidence-explanation">The reference lists several anti-IL-1 therapies as beneficial for colchicine-resistant or intolerant FMF patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36161616" target="_blank">PMID:36161616</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance."</div>
                
                
                <div class="evidence-explanation">The study supports the effectiveness of anti-IL-1 therapy in managing inflammation in colchicine-resistant FMF patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    NSAIDs
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used for symptom relief during acute attacks</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37752496" target="_blank">PMID:37752496</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"These provide the basis for stratifying patients into the following treatment paths: continue colchicine, persisting attacks / inflammation, colchicine intolerance, persisting arthritis, colchicine reduction and adjustment/reduction of biologics."</div>
                
                
                <div class="evidence-explanation">The literature does not mention NSAIDs as a treatment path for symptom relief during acute attacks of Familial Mediterranean Fever. The focus is on colchicine and biological therapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36945975" target="_blank">PMID:36945975</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mean age of the overall group was 38.2 +/- 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order)."</div>
                
                
                <div class="evidence-explanation">There is no mention of NSAIDs being used for symptom relief during acute attacks in FMF patients. The treatments focus on colchicine and IL-1 antagonist.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lifestyle Modifications
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Avoiding known triggers such as stress and infections where possible</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38488998" target="_blank">PMID:38488998</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients can significantly decrease the number of familial Mediterranean fever attacks they experience by managing psychological stress and avoiding physical factors such as cold exposure and fatigue."</div>
                
                
                <div class="evidence-explanation">The literature supports the management of psychological stress and avoiding physical factors as triggers but does not explicitly mention infections.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26324575" target="_blank">PMID:26324575</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Triggers of this illness include many things, such as cold or stress."</div>
                
                
                <div class="evidence-explanation">The literature mentions stress as a trigger but does not provide exhaustive confirmation about infections as triggers or other preventive lifestyle modifications.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Physical Stress</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22234484" target="_blank">PMID:22234484</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple stressful life events predicted FMF attacks 2 days following the event. ... Physical exertion and high-fat diet did not increase the likelihood of FMF attacks."</div>
                
                
                <div class="evidence-explanation">The study found that emotional stress could trigger FMF attacks, but physical stress did not show a significant effect. Therefore, while stress in general may trigger episodes, physical stress specifically does not.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Emotional Stress</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22234484" target="_blank">PMID:22234484</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple stressful life events predicted FMF attacks 2 days following the event. After adjustment for treatment, an additional stressful event was associated with an estimated 70% increase in the odds of having an FMF attack on the second day."</div>
                
                
                <div class="evidence-explanation">The study indicates a clear association between emotional stress and the triggering of FMF attacks, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33026080" target="_blank">PMID:33026080</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The emergence of FMF attacks after emotional stress and the induction of attacks with metaraminol in previous decades suggested that stress-induced sympathoadrenal system activation might play a role in inflammasome activation and triggering attacks."</div>
                
                
                <div class="evidence-explanation">The literature provides evidence that emotional stress can trigger FMF attacks through the activation of the inflammasome pathway.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Familial Mediterranean Fever
category: Genetic
parents:
- Autoinflammatory Disease
- Inherited Disorder
has_subtypes:
- name: Type 1
  description: Classic form presenting with recurrent episodes of fever and serositis.
  evidence:
  - reference: PMID:25649364
    supports: NO_EVIDENCE
    snippet: Familial Mediterranean Fever is an autosomal recessive inherited disease
      with a course of autoinflammation, which is characterized by the episodes of
      fever and serositis.
    explanation: Although the literature describes Familial Mediterranean Fever having
      episodic fever and serositis, it does not define subtypes or a &#39;Type 1&#39; specifically.
  - reference: PMID:23823268
    supports: NO_EVIDENCE
    snippet: Periodic fevers are acquired or inherited disorders of innate immunity,
      which were first described in the 1940s. ... This clinical review focuses on
      a sample of autoinflammatory disorders including familial Mediterranean fever...
    explanation: There is a general discussion of Familial Mediterranean Fever but
      no mention of subtypes or a classification system involving the term &#39;Type 1&#39;.
  - reference: PMID:36889987
    supports: NO_EVIDENCE
    snippet: MEFV gene mutation spectrum in patients with familial mediterranean fever.
    explanation: This study discusses the gene mutations associated with FMF but does
      not describe subtypes of the disease.
- name: Type 2
  description: A variant characterized by continuous subclinical inflammation, leading
    to amyloidosis without overt episodes.
  evidence:
  - reference: PMID:21358337
    supports: SUPPORT
    snippet: Familial Mediterranean fever type 2 is characterized by amyloidosis as
      the first clinical manifestation of familial Mediterranean fever in an otherwise
      asymptomatic individual.
    explanation: The literature directly states that FMF type 2 is characterized by
      amyloidosis without prior overt inflammatory episodes, aligning with the given
      statement.
  - reference: PMID:11053071
    supports: PARTIAL
    snippet: Phenotype II in familial Mediterranean fever (FMF) is the onset of amyloidosis
      before the onset of FMF with its typical attacks, or as an isolated finding
      in a member of an FMF family.
    explanation: While this states Type 2 can involve amyloidosis without typical
      attacks, it does not directly mention continuous subclinical inflammation.
  - reference: PMID:36161616
    supports: PARTIAL
    snippet: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with
      colchicine resistance, however, it is not certain whether subclinical inflammation
      can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis.
    explanation: Reference to subclinical inflammation in amyloidosis supports part
      of the statement, but does not specifically mention Type 2 FMF.
  - reference: PMID:37496356
    supports: PARTIAL
    snippet: Recent studies have shown that cases of amyloidosis in patients with
      familial Mediterranean fever are decreasing
    explanation: Though it implies a relationship between FMF and amyloidosis, it
      does not clearly distinguish between subtypes or mention continuous subclinical
      inflammation.
prevalence:
- population: Mediterranean Populations
  percentage: 0.1-0.2
  evidence:
  - reference: PMID:32608308
    supports: REFUTE
    snippet: The predominant ethnicities were Turkish (41.8%), Lebanese (15.8%), Syrian
      (6.5%), South-West Asian (7.9%), and South-East Asian (3.0%).
    explanation: The prevalence in Mediterranean populations, such as Turkish (41.8%)
      and Lebanese (15.8%), is much higher than 0.1-0.2%.
  - reference: PMID:11053071
    supports: NO_EVIDENCE
    snippet: Phenotype II is uncommon among the relatives of patients with FMF and
      amyloidosis.
    explanation: This study does not provide direct evidence on the overall prevalence
      of FMF in the Mediterranean populations.
  - reference: PMID:3306755
    supports: REFUTE
    snippet: Recurrent hereditary polyserositis (RHP) or familial Mediterranean fever
      (FMF) is a chronic inherited illness of obscure aetiology... and predominantly
      affects Sephardic Jews, Arabs, Turks and Armenians.
    explanation: The article suggests that FMF predominantly affects specific Mediterranean
      populations, implying a higher prevalence than 0.1-0.2% among these groups.
  - reference: PMID:34363075
    supports: NO_EVIDENCE
    snippet: The aim of this study was to determine the prevalence of FMF in children
      with cryptogenic cirrhosis and it was found to be high, to add FMF among the
      etiological causes of cirrhosis
    explanation: The study focused on children with cryptogenic cirrhosis and does
      not provide general prevalence data for Mediterranean populations.
progression:
- phase: Onset
  age_range: Childhood-Adolescence
  evidence:
  - reference: PMID:31999206
    supports: SUPPORT
    snippet: Of 1687 patients, 761 had first FMF attack at &lt;/=3 years of age while
      926 patients presented with their first manifestation of FMF at &gt;3 years.
    explanation: The study provides evidence that FMF onset can occur in childhood.
  - reference: PMID:23194659
    supports: SUPPORT
    snippet: Median age at first symptoms was 4 years (range 3 month-37 years) and
      at diagnosis 10 years (range 2-44 years).
    explanation: This reference supports the statement by indicating that the majority
      of FMF cases have an onset in childhood.
pathophysiology:
- name: MEFV Gene Mutation
  description: Mutations in the MEFV gene lead to dysfunctional pyrin, causing excessive
    inflammation.
  gene:
    preferred_term: MEFV
  evidence:
  - reference: PMID:28154935
    supports: SUPPORT
    snippet: Familial Mediterranean fever (FMF) is caused by mutations within the
      Mediterranean fever (MEFV) gene. These gain of function mutations lead to an
      increased activation of the inflammasome pyrin with a subsequent disproportional
      proinflammatory reaction.
    explanation: Mutations in the MEFV gene result in increased activation of pyrin,
      causing excessive inflammation.
  - reference: PMID:25307949
    supports: SUPPORT
    snippet: Mutations in the MEFV gene are associated with the human autoinflammatory
      disease familial Mediterranean fever (FMF). Pyrin can interact with the inflammasome
      adaptor ASC and induce inflammatory caspase-1 activation in monocytic cells.
    explanation: This article discusses the role of pyrin in inducing inflammatory
      responses, supporting the effect of MEFV gene mutations in causing excessive
      inflammation.
  - reference: PMID:36889987
    supports: SUPPORT
    snippet: MEFV gene mutation spectrum in patients with familial mediterranean fever
    explanation: The mutation spectrum in the MEFV gene is related to the pathogenesis
      involving pyrin and inflammation, supporting the given statement.
- name: Autoinflammatory Pathway Activation
  description: Dysregulated inflammatory response due to pyrin dysfunction, leading
    to recurrent inflammatory episodes.
  pathways:
  - preferred_term: IL-1β
    term:
      id: GO:0032611
      label: interleukin-1 beta production
  - preferred_term: inflammasome
  evidence:
  - reference: PMID:16344627
    supports: SUPPORT
    snippet: The spectrum of reported genetic mutations and susceptible ethnicities
      for the hereditary periodic fever subset of the autoinflammatory diseases has
      continued to expand. At the same time, the pathogeneses of many of these diseases
      are now understood to involve different aspects of a common pathway, largely
      affecting inflammatory cascades related to IL-1 or tumor necrosis factor-alpha.
    explanation: This reference supports the involvement of IL-1 and inflammatory
      pathways in autoinflammatory diseases, including Familial Mediterranean Fever
      (FMF).
  - reference: PMID:29148036
    supports: SUPPORT
    snippet: Pyrin, encoded by the MEFV gene, is an intracellular pattern recognition
      receptor that assembles inflammasome complexes in response to pathogen infections.
      Mutations in the MEFV gene have been linked to autoinflammatory diseases such
      as familial Mediterranean fever (FMF) or pyrin-associated autoinflammation with
      neutrophilic dermatosis (PAAND).
    explanation: This reference describes the role of pyrin in inflammasome activation
      and its link to FMF, supporting the statement about dysregulated inflammatory
      responses and recurrent inflammatory episodes.
  - reference: PMID:33026080
    supports: SUPPORT
    snippet: FMF is an autoinflammatory disease characterized by recurrent attacks
      and increased IL-1 synthesis owing to activation of the pyrin inflammasome
    explanation: This reference directly mentions recurrent attacks and increased
      IL-1 synthesis due to pyrin inflammasome activation, supporting the mechanisms
      described in the statement.
  - reference: PMID:32601469
    supports: SUPPORT
    snippet: Familial Mediterranean fever (FMF) is an autoinflammatory disease caused
      by homozygous or compound heterozygous gain-of-function mutations in MEFV, which
      encodes pyrin, an inflammasome protein. Heterozygous carrier frequencies for
      multiple MEFV mutations are high in several Mediterranean populations, suggesting
      that they confer selective advantage.
    explanation: This reference supports the genetic basis of FMF involving mutations
      in MEFV, which leads to the dysregulated inflammatory response observed in FMF.
  - reference: PMID:29051974
    supports: SUPPORT
    snippet: Familial Mediterranean fever (FMF) is an autoinflammatory disease manifested
      by inflammatory attacks of peritonitis, pleuritis, pericarditis accompanied
      by fever and arthritis. Mutations of MEFV gene results in pyrin dysfunction,
      which causes uncontrolled interleukin-1 beta production and triggers the inflammatory
      attacks.
    explanation: This reference supports the mechanism described in the statement,
      emphasizing pyrin dysfunction and the uncontrolled production of interleukin-1
      beta.
phenotypes:
- category: Systemic
  name: Recurrent Fever
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:21358337
    supports: PARTIAL
    snippet: Familial Mediterranean fever type 1 is characterized by recurrent short
      episodes of inflammation and serositis, including fever, peritonitis, synovitis,
      pleuritis, and, rarely, pericarditis.
    explanation: The literature supports that recurrent fever is a common feature
      of Familial Mediterranean Fever type 1, but it does not fully support that FMF
      should be categorized solely under systemic phenotypes.
  - reference: PMID:25832989
    supports: PARTIAL
    snippet: Familial Mediterranean fever...presents with recurrent and self-limited
      inflammatory attacks of fever and polyserositis along with high acute-phase
      reactants.
    explanation: The literature supports that recurrent fever is a common diagnostic
      feature of FMF and systemically involves fever and inflammation, but it does
      not confirm all specified aspects of the statement.
  - reference: PMID:36688581
    supports: PARTIAL
    snippet: Higher Pras scores, earlier age of symptoms and diagnosis, more frequent
      arthritis and erysipelas-like erythema, and higher colchicine dose are closely
      associated with M694V homozygous familial Mediterranean fever patients. These
      patients also have mostly moderate and severe disease severity.
    explanation: It supports the systemic nature and severity aspects but does not
      fully align with the complete statement&#39;s focus.
  - reference: PMID:34606655
    supports: PARTIAL
    snippet: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory
      disease manifesting with phenotypic heterogeneity. It is a clinically diagnosed
      disease supported by Mediterranean fever gene mutation analysis.
    explanation: While fever is a prominent symptom, FMF is known for phenotypic heterogeneity,
      indicating varied systemic manifestations.
  phenotype_term:
    preferred_term: Recurrent Fever
    term:
      id: HP:0001954
      label: Recurrent fever
- category: Musculoskeletal
  name: Arthritis
  frequency: FREQUENT
  notes: Transient, affecting large joints
  evidence:
  - reference: PMID:11411958
    supports: SUPPORT
    snippet: The arthritis was transient, monoarticular, nonerosive, and nondeforming
      in the majority of cases. Four patients (5.4%) had chronic arthritis, with one
      requiring total hip replacement. As in previous reports on arthritis of FMF,
      the majority of FMF patients studied in Lebanon had a transient monoarticular
      nonerosive and nondeforming type of arthritis affecting predominantly the large
      joints of the lower extremities.
    explanation: This reference supports the statement that arthritis is a common
      phenotype in FMF, is transient, and affects large joints.
  - reference: PMID:33124556
    supports: SUPPORT
    snippet: More patients had arthritis in the ELE group than in the other group
      (p=0.011). Arthritis occurred in the ankle (77.4%), knee (19.3%) and hip (3.2%)
      joints.
    explanation: This reference confirms the presence of arthritis in FMF patients,
      especially in large joints, supporting the statement.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
- category: Gastrointestinal
  name: Peritonitis
  frequency: VERY_FREQUENT
  notes: Recurrent abdominal pain due to inflammation of the peritoneum
  evidence:
  - reference: PMID:36082189
    supports: PARTIAL
    snippet: FMF is characterised by dysregulation of the inflammatory process in
      the body, presenting as recurrent episodes of serositis. Patients with FMF commonly
      present with episodes of fever, peritonitis, synovitis, pleuritis, arthritis,
      and occasionally pericarditis.
    explanation: This reference supports that peritonitis, which involves abdominal
      pain due to inflammation of the peritoneum, is a phenotype of FMF. However,
      it does not explicitly indicate a high frequency of gastrointestinal phenotypes.
  - reference: PMID:37723615
    supports: PARTIAL
    snippet: Familial Mediterranean fever (FMF) is the most prevalent hereditary autoinflammatory
      disease among children. Abdominal pain and various gastrointestinal system (GIS)
      manifestations may arise directly from FMF or concomitantly with FMF.
    explanation: This reference supports that gastrointestinal manifestations, including
      abdominal pain, are phenotypes of FMF. However, it does not specify the high
      frequency of peritonitis.
  - reference: PMID:9562837
    supports: SUPPORT
    snippet: When a patient complains of episodic fever accompanied by unexplained
      arthritis, peritonitis, pleurisy, or skin rash, this disorder should be considered.
    explanation: This reference supports that peritonitis is a common phenotype of
      FMF, aligning well with the statement.
  - reference: PMID:35737103
    supports: SUPPORT
    snippet: The key feature of familial Mediterranean fever is relapsing episodes
      of fever and serositis including peritonitis, pleurisy, or arthritis.
    explanation: This reference clearly supports that peritonitis, involving abdominal
      pain due to inflammation of the peritoneum, is a key feature of FMF and occurs
      frequently.
  - reference: PMID:31308342
    supports: SUPPORT
    snippet: Considering the history of recurrent abdominal pain, Familial Mediterranean
      Fever (FMF) was considered.
    explanation: This reference supports that recurrent abdominal pain is a phenotype
      associated with FMF.
  phenotype_term:
    preferred_term: Peritonitis
    term:
      id: HP:0002586
      label: Peritonitis
- category: Thoracic
  name: Pleuritis
  frequency: FREQUENT
  notes: Recurrent chest pain due to inflammation of the pleura
  evidence:
  - reference: PMID:38204312
    supports: SUPPORT
    snippet: The most common signs and symptoms are fever, abdominal pain, chest pain,
      and arthritis.
    explanation: The study highlights chest pain as a frequent symptom in FMF patients,
      indicating pleuritis as a common phenotype.
  - reference: PMID:12092043
    supports: SUPPORT
    snippet: Lung involvement in FMF is limited mainly to transient pleuritis during
      acute attacks.
    explanation: The study specifies that pleuritis, which is inflammation of the
      pleura, is a frequent thoracic phenotype in FMF.
  - reference: PMID:36385047
    supports: SUPPORT
    snippet: Pericarditis, pleurisy and the response to colchicine indicated FMF.
    explanation: This study identifies pleurisy, another term for pleuritis, as a
      characteristic symptom in FMF patients, supporting the statement.
  - reference: PMID:36725780
    supports: PARTIAL
    snippet: Pleuritis is the only known pulmonary involvement of FMF; however, as
      far as we know, thoracic involvements in pleural, parenchymal, bronchial, and
      vascular structures have not been evaluated yet.
    explanation: While the study acknowledges pleuritis as a known pulmonary involvement
      in FMF, it does not provide evidence on its frequency being &#34;FREQUENT&#34;.
  phenotype_term:
    preferred_term: Pleuritis
    term:
      id: HP:0002102
      label: Pleuritis
- category: Renal
  name: Amyloidosis
  frequency: OCCASIONAL
  notes: Can lead to kidney failure if untreated
  evidence:
  - reference: PMID:12832747
    supports: SUPPORT
    snippet: Amyloidosis, causing renal failure, is one of the most severe complications
      of the disease.
    explanation: The literature confirms that amyloidosis can lead to kidney failure
      in patients with Familial Mediterranean Fever (FMF), supporting the statement.
  - reference: PMID:23548761
    supports: SUPPORT
    snippet: Familial Mediterranean Fever and tuberculosis were the most frequent
      causes of amyloidosis.
    explanation: The statement is supported as FMF is listed as one of the frequent
      causes of renal amyloidosis.
  - reference: PMID:21360109
    supports: SUPPORT
    snippet: The most frequent cause [of renal amyloidosis in children] is now autoinflammatory
      diseases. Among this group of diseases, the most frequent one throughout the
      world is familial Mediterranean fever (FMF).
    explanation: This confirms that FMF is a frequent cause of renal amyloidosis,
      thereby supporting the statement.
  - reference: PMID:33052444
    supports: SUPPORT
    snippet: Amyloidosis [...] stands out as a major complication of familial Mediterranean
      fever (FMF). Splenic and renal involvement is more likely in FMF-associated
      systemic amyloidosis.
    explanation: The literature confirms the renal involvement in FMF-associated amyloidosis,
      thus supporting the statement.
  phenotype_term:
    preferred_term: Amyloidosis
    term:
      id: HP:0011034
      label: Amyloidosis
- category: Integumentary
  frequency: OCCASIONAL
  name: Erysipelas-Like Erythema
  notes: Recurrent erythematous skin lesions, usually on the lower legs
  evidence:
  - reference: PMID:21352275
    supports: SUPPORT
    snippet: Erysipelas-like erythema with familial Mediterranean fever.
    explanation: The title itself indicates a connection between erysipelas-like erythema
      and familial Mediterranean fever.
  - reference: PMID:33124556
    supports: SUPPORT
    snippet: Erysipelas-like erythema (ELE) is a well-known pathognomonic skin lesion
      associated with familial Mediterranean fever (FMF).
    explanation: The study describes ELE as a significant feature of FMF, supporting
      the statement that it is an occasional manifestation in the integumentary system.
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Myalgia
  notes: Muscle pain, often in the legs, associated with fever episodes
  evidence:
  - reference: PMID:37309906
    supports: SUPPORT
    snippet: Recurrent fever, serositis, and arthritis are common findings of the
      disease. In addition, musculoskeletal complaints such as exertional leg pain
      can be overlooked, although they are common and affect patients&#39; quality of
      life.
    explanation: The literature mentions musculoskeletal complaints, including exertional
      leg pain, as common in FMF, supporting the statement that myalgia is an occasional
      symptom.
  - reference: PMID:32895731
    supports: SUPPORT
    snippet: Protracted febrile myalgia syndrome (PFMS) is one of the rare conditions
      characterized by long standing severe myalgia and fever in familial Mediterranean
      fever (FMF) patients.
    explanation: This reference specifically mentions severe myalgia as a symptom
      in FMF patients, which supports the statement.
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
diagnosis:
- name: Genetic Testing
  results: Identifies MEFV mutations
  evidence:
  - reference: PMID:29314663
    supports: PARTIAL
    snippet: Even though clinical assessment is accepted to be the most important
      factor in the diagnosis of FMF... MEFV gene assessment, unlike other diagnostic
      procedures, might support physicians in the early diagnosis of FMF.
    explanation: The literature acknowledges the importance of genetic testing for
      MEFV mutations but emphasizes that clinical evaluation remains crucial for diagnosis
      overall.
  - reference: PMID:25649364
    supports: SUPPORT
    snippet: Genetic mutation of the disease is on MEFV gene located on short arm
      of Chromosome 16. The disease is diagnosed based on clinical evaluation.
    explanation: This reference supports the statement that MEFV mutations are identified
      through genetic testing, although it specifies that the diagnosis is based on
      clinical evaluation.
  - reference: PMID:12168253
    supports: SUPPORT
    snippet: This strategy allows definitive confirmation of periodic disease if one
      mutation is detected on each of the two chromosomes...
    explanation: This reference directly supports the use of genetic testing to identify
      MEFV mutations for diagnosing familial Mediterranean fever.
  - reference: PMID:33037005
    supports: SUPPORT
    snippet: Its diagnosis relies on a set of clinical criteria and a genetic confirmation
      on identification of biallelic pathogenic MEFV variants.
    explanation: The reference confirms that genetic testing for MEFV mutations is
      a key part of diagnosing familial Mediterranean fever.
- name: Inflammatory Markers
  presence: Elevated
  markers: CRP, ESR, SAA
  evidence:
  - reference: PMID:31524848
    supports: SUPPORT
    snippet: Median values of acute phase reactants during FMF attacks were 433.5
      mg/L ... for serum amyloid A (SAA), 56.7 mg/L ... for C-reactive protein (CRP),
      and 37.5 mm/h ... for erythrocyte sedimentation rate (ESR).
    explanation: The study shows that SAA, CRP, and ESR are elevated during FMF attacks.
  - reference: PMID:23794006
    supports: SUPPORT
    snippet: We found that the NLR values of the patients were significantly higher
      than those of the control group, and C-reactive protein values were correlated
      with NLR.
    explanation: CRP is confirmed as an elevated marker in FMF patients in this study
      as well.
environmental:
- name: Physical Stress
  effect: May trigger episodes
  evidence:
  - reference: PMID:22234484
    supports: PARTIAL
    snippet: Multiple stressful life events predicted FMF attacks 2 days following
      the event. ... Physical exertion and high-fat diet did not increase the likelihood
      of FMF attacks.
    explanation: The study found that emotional stress could trigger FMF attacks,
      but physical stress did not show a significant effect. Therefore, while stress
      in general may trigger episodes, physical stress specifically does not.
- name: Emotional Stress
  effect: Potential trigger for flare-ups
  evidence:
  - reference: PMID:22234484
    supports: SUPPORT
    snippet: Multiple stressful life events predicted FMF attacks 2 days following
      the event. After adjustment for treatment, an additional stressful event was
      associated with an estimated 70% increase in the odds of having an FMF attack
      on the second day.
    explanation: The study indicates a clear association between emotional stress
      and the triggering of FMF attacks, supporting the statement.
  - reference: PMID:33026080
    supports: SUPPORT
    snippet: The emergence of FMF attacks after emotional stress and the induction
      of attacks with metaraminol in previous decades suggested that stress-induced
      sympathoadrenal system activation might play a role in inflammasome activation
      and triggering attacks.
    explanation: The literature provides evidence that emotional stress can trigger
      FMF attacks through the activation of the inflammasome pathway.
treatments:
- name: Colchicine
  description: First-line treatment to prevent and reduce the frequency of attacks
    and the risk of amyloidosis.
  evidence:
  - reference: PMID:19797919
    supports: SUPPORT
    snippet: The study demonstrated that colchicine treatment is effective in preventing
      amyloidosis among Armenian patients with FMF and that earlier initiation and
      continuous therapy at an adequate dose of 1.2-1.8 mg/day may be associated with
      a decreased amyloidosis risk among Armenian patients with FMF.
    explanation: The study directly supports the statement that colchicine is a first-line
      treatment for preventing amyloidosis, a common complication of FMF.
  - reference: PMID:25649364
    supports: SUPPORT
    snippet: The only agent that decreases the development of amyloidosis and the
      frequency and severity of the episodes is colchicine, which has been used for
      about 40 years.
    explanation: This reference clearly supports the claim that colchicine reduces
      the frequency of attacks and prevents amyloidosis, affirming its role as a first-line
      treatment.
  - reference: PMID:25791871
    supports: SUPPORT
    snippet: Early studies reported colchicine as a potential drug for preventing
      attacks of familial Mediterranean fever.
    explanation: This indicates that colchicine is considered effective for preventing
      FMF attacks, supporting its position as a first-line treatment.
  - reference: PMID:17242135
    supports: SUPPORT
    snippet: The daily application of colchicine is the standard therapy for prophylaxis
      of attacks and amyloid deposition in familial Mediterranean fever.
    explanation: This statement corroborates that colchicine is the standard, or first-line,
      therapy for preventing FMF attacks and amyloidosis.
  - reference: PMID:15720245
    supports: SUPPORT
    snippet: Since 1972 colchicine has become the drug of choice for prophylaxis against
      FMF attacks and amyloidosis FMF-associated.
    explanation: This reference supports the idea that colchicine is the primary treatment
      for preventing FMF attacks and associated amyloidosis.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Anti-IL-1 Therapy
  description: Used in colchicine-resistant cases to control inflammation (e.g., anakinra,
    canakinumab).
  evidence:
  - reference: PMID:28362189
    supports: SUPPORT
    snippet: The accumulating data indicates that anti IL-1 drugs are effective in
      treating colchicine resistant FMF cases and improving their quality of life.
    explanation: The reference supports the use of anti-IL-1 therapy for treating
      colchicine-resistant FMF cases.
  - reference: PMID:30338514
    supports: SUPPORT
    snippet: For those people who are colchicine-resistant or intolerant, drugs such
      as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and
      interferon-alpha might be beneficial.
    explanation: The reference lists several anti-IL-1 therapies as beneficial for
      colchicine-resistant or intolerant FMF patients.
  - reference: PMID:36161616
    supports: SUPPORT
    snippet: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with
      colchicine resistance.
    explanation: The study supports the effectiveness of anti-IL-1 therapy in managing
      inflammation in colchicine-resistant FMF patients.
  - reference: PMID:27860460
    supports: SUPPORT
    snippet: In this randomized controlled trial, anakinra appears to be an effective
      and safe treatment for colchicine-resistant FMF.
    explanation: The reference provides evidence from a randomized controlled trial
      supporting the effectiveness of anakinra, an anti-IL-1 therapy, in colchicine-resistant
      FMF patients.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: NSAIDs
  description: Used for symptom relief during acute attacks
  evidence:
  - reference: PMID:37752496
    supports: REFUTE
    snippet: &#39;These provide the basis for stratifying patients into the following
      treatment paths: continue colchicine, persisting attacks / inflammation, colchicine
      intolerance, persisting arthritis, colchicine reduction and adjustment/reduction
      of biologics.&#39;
    explanation: The literature does not mention NSAIDs as a treatment path for symptom
      relief during acute attacks of Familial Mediterranean Fever. The focus is on
      colchicine and biological therapy.
  - reference: PMID:36945975
    supports: NO_EVIDENCE
    snippet: Mean age of the overall group was 38.2 +/- 11.7 years (62.4% female,
      37.6% male). Two hundred and twenty-seven patients were treated with colchicine,
      97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only
      with IL-1 antagonist (67.1%, 26.3%, 6.64% in order).
    explanation: There is no mention of NSAIDs being used for symptom relief during
      acute attacks in FMF patients. The treatments focus on colchicine and IL-1 antagonist.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Lifestyle Modifications
  description: Avoiding known triggers such as stress and infections where possible
  evidence:
  - reference: PMID:38488998
    supports: PARTIAL
    snippet: Patients can significantly decrease the number of familial Mediterranean
      fever attacks they experience by managing psychological stress and avoiding
      physical factors such as cold exposure and fatigue.
    explanation: The literature supports the management of psychological stress and
      avoiding physical factors as triggers but does not explicitly mention infections.
  - reference: PMID:26324575
    supports: PARTIAL
    snippet: Triggers of this illness include many things, such as cold or stress.
    explanation: The literature mentions stress as a trigger but does not provide
      exhaustive confirmation about infections as triggers or other preventive lifestyle
      modifications.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
disease_term:
  preferred_term: familial Mediterranean fever
  term:
    id: MONDO:0018088
    label: familial Mediterranean fever
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Familial_Mediterranean_Fever.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>